Kenvue Inc. (NYSE:KVUE) is Kennon Green & Company LLC's 9th Largest Position

Kennon Green & Company LLC lifted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 22.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 210,148 shares of the company's stock after purchasing an additional 38,613 shares during the period. Kenvue accounts for about 4.1% of Kennon Green & Company LLC's investment portfolio, making the stock its 9th biggest position. Kennon Green & Company LLC's holdings in Kenvue were worth $5,039,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new position in Kenvue in the fourth quarter valued at $521,348,000. Starboard Value LP acquired a new stake in Kenvue in the fourth quarter valued at $467,864,000. Franklin Resources Inc. lifted its stake in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE traded up $0.05 during trading on Tuesday, reaching $20.98. 17,882,871 shares of the company were exchanged, compared to its average volume of 16,130,834. The company's 50-day moving average is $22.73 and its two-hundred day moving average is $22.34. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The company has a market cap of $40.25 billion, a price-to-earnings ratio of 38.15, a P/E/G ratio of 3.24 and a beta of 0.98. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business's revenue was down 3.9% on a year-over-year basis. During the same quarter last year, the business posted $0.28 EPS. Research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.91%. Kenvue's payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Barclays boosted their price objective on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. UBS Group raised their target price on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Friday, May 9th. Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Finally, Citigroup restated a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of "Hold" and a consensus price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.